An Open-label, Multi-center, Phase 1b/2 Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors.
Phase of Trial: Phase I/II
Latest Information Update: 29 Nov 2019
Price : $35 *
At a glance
- Drugs Copanlisib (Primary) ; Nivolumab
- Indications Colorectal cancer; Head and neck cancer; Liver cancer; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bayer
- 26 Nov 2019 Planned End Date changed from 30 Apr 2021 to 20 Dec 2022.
- 26 Nov 2019 Planned primary completion date changed from 30 Apr 2021 to 20 Dec 2022.
- 07 Dec 2018 Status changed from not yet recruiting to recruiting.